People with melanoma often have mole-looking growths on their skin that tend to be irregular in shape and colour and can be hard to tell apart from benign ones, making the disease difficult to diagnose.
"There is a real need for standardisation across the field of dermatology in how melanomas are evaluated," said James Krueger, Professor at Rockefeller University in the US.
"Detection through screening saves lives but is very challenging visually, and even when a suspicious lesion is extracted and biopsied, it is confirmed to be melanoma in only about 10 per cent of cases," said Krueger.
The analysis generates an overall risk score, called a Q-score, which indicates the likelihood that the growth is cancerous.
A recent study evaluating the tool's usefulness indicates that the Q-score yields 98 per cent sensitivity, meaning it is very likely to correctly identify early melanomas on the skin.
The ability of the test to correctly diagnose normal moles was 36 per cent, approaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.
The researchers developed this tool by feeding 60 photos of cancerous melanomas and an equivalent batch of pictures of benign growths into image processing programmes.
They developed imaging biomarkers to precisely quantify visual features of the growths.
Using computational methods, they generated a set of quantitative metrics that differed between the two groups of images - essentially identifying what visual aspects of the lesion mattered most in terms of malignancy - and gave each biomarker a malignancy rating.
As previous studies have shown, the number of colours in a lesion turned out to be the most significant biomarker for determining malignancy.
Some biomarkers were significant only if looked at in specific colour channels - a finding the researchers say could potentially be exploited to identify additional biomarkers and further improve accuracy.
"I think this technology could help detect the disease earlier, which could save lives, and avoid unnecessary biopsies too," said Gareau.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
